Global Research Antibodies Market - 2022-2029

Global Research Antibodies Market - 2022-2029
Market Overview

Research Antibodies Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Research antibodies are proteins that are mainly used in numerous research fields, diagnostic investigations, and even the development of treatments. Due to their capacity for binding to particular molecular variations, these proteins are used in cell research and development to aid in efficiently isolating and identifying cells. Research antibodies help people understand how the protein functions in cells.

Market Dynamics

The increase in research and development by various biopharmaceutical and pharmaceutical companies is expected to drive market growth.

Y-Biologics and Pascal Biosciences Inc., two pharmaceutical companies, have agreed to collaborate on finding and creating innovative bio-specific antibodies. According to the agreement, Pascal Biosciences Inc. will use Y-Biologics' antibodies and contribute their innovative Alice antibody platform technology. Moreover, Abcam announced its partnership with Twist Bioscience, a provider of high-quality synthetic DNA, in February 2022, intending to enhance antibody discovery for diagnostic and research uses. Additionally, the FDA approved the clinical use of DNA-encoded monoclonal antibody (DMAb) therapy in 2019 to prevent Zika virus infection. The DMAb used in the therapy is produced inside the body, in contrast to traditional therapeutic antibodies created in industrial facilities. DNA instructions are given to patients so that their bodies can create their own highly specialized antibodies to fight infection and arm themselves with the appropriate equipment. The pathogenic targets attacked by the antibodies produced include bacteria, cancer cells, and virus-infected cells. A clinical shift in antibody therapy is being brought about by DMAb therapy. Recently, thorough DMAb preclinical research has been carried out, leading to successful DMAb in vivo production. A significant improvement over conventional monoclonal antibody therapy is possible with the new strategy. Furthermore, DMAb therapy may increase the range of antibody treatments, creating new patient populations for antibody-based therapies to diagnose or treat diseases. Thus, from the above statements, the market is expected to drive in the forecast period.

Limitations associated with the research antibodies are expected to hamper the market growth.

Commercial research antibodies are crucial tools in modern cell biology and biochemistry. Around $2 billion is spent on them in the USA each year. But many are not fit for purpose, which may contribute to the reproducibility crisis in biological sciences. Suppliers' inadequate antibody validation and characterization, lack of user awareness, and occasional incompetence have had immense scientific and personal costs. Therefore, from the above statements, the market is expected to get hampered in the forecast period.

Industry Analysis

The research antibodies market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, epidemiology etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted the market. Several large pharmaceutical companies are investing heavily in R&D to create brand-new vaccinations, treatments, and testing tools for this pandemic. The need for research antibodies has greatly expanded due to these intense R&D initiatives for creating innovative vaccines and therapeutic strategies. FDA approvals for the treatment of new strains of COVID-19 are also available. For instance, On February 11, 2022, the U.S. Food and Drug Administration granted an emergency use authorization (EUA) for a novel monoclonal antibody to treat COVID-19 that still exhibits action against the omicron form. The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older, weighing at least 40 kilograms, or 88 pounds) who have a positive COVID-19 test and are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not readily available or clinically appropriate. Thus, from the above statements, the market is expected to boost in the forecast period.

Segment Analysis

Western Blotting segment is expected to hold the largest market share in research antibodies market

The western blotting segment accounted for the largest market share in 2021. The segment benefits because it is often used in research to separate and identify proteins. This technique separates a mixture of proteins based on molecular weight and thus by type through gel electrophoresis. These results are then transferred to a membrane producing a band for each protein. Moreover, due to the higher accuracy offered by the western blotting technique, it is frequently chosen over alternative technologies for detecting HIV antibodies, including ELISA tests and flow cytometry. Therefore, it has increased the demand for the western blotting technique, and the segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global research antibodies market

In 2021, the North American research antibodies accounted for the highest revenue share in the global market. The increasing prevalence of cancer and neurological diseases, the presence of key market players and increased investment in R&D activities, rising demand for personalized medicine, technological advancements in proteomics research and growing focus on biomedical, stem cell and cancer research are the factors in the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, In 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the focus on biomedical, stem cell and cancer research.

Moreover, the All of Us Research Program announced more funding to develop precision medicine on May 23, 2022. Subject to the availability of money and the caliber of the proposals, the program plans to contribute up to $2 million in Fiscal Year (FY) 22 to fund up to 20 awards. It encourages projects that address high-priority areas identified by NIH partners in the NOSI, including COVID-19 exposure, treatment, and post-acute sequelae of SARS CoV-2 (long COVID). In addition, Merck Millipore announced in February 2022 that it would acquire Exelead for about US$ 780 million. Through this agreement, Merck's Life Science business unit will be able to provide end-to-end CDMO services for the entire mRNA value chain to its clients.

Competitive Landscape

Major key players in the research antibodies market are Abcam Plc, Agilent Technologies, Bio-rad Laboratories, Becton Dickinson & Company, Cell Signalling Technology, Inc., F. Hoffmann La Roche Ltd., Lonza Group, Thermo Fisher Scientific, Perkinelmer Inc., Merck Millipore.

Emulate, Inc.:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and based in Waltham, Massachusetts. The company offers worldwide life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

Cancer Research Antibodies: The Company offers primary antibodies for studying various targets in cancer research. Regardless of whether the study is centered on tumor suppressors, proliferative signaling, apoptosis, autophagy, metabolism, inflammation, or any other topic linked to cancer. Invitrogen cancer research antibodies are designed to detect the key cancer targets dependably. Each antibody is validated for use in various applications. Some featured cancer research antibody targets and categories include:
• MAPK Signaling Pathway Antibodies
• AKT Signaling Pathway Antibodies
• Phosphospecific Antibodies
• Transcription-Specific Antibodies

GTPase Antibodies

The global research antibodies market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.